The U.S. Food and Drug Administration issued a Complete Response Letter on April 10 2026 that rejected Replimune Group’s oncolytic virus RP1 for advanced melanoma. This decision follows a prior CRL issued on July 22 2025, making it the second regulatory setback for the candidate.
The FDA’s letter cited deficiencies in the adequacy and control of the IGNYTE and IGNYTE‑3 clinical trials and the inability to isolate RP1’s contribution when combined with nivolumab. Manufacturing and quality issues were not the primary concern, contrary to the original article’s emphasis.
The rejection removes the possibility of a pivotal approval that would have opened a multi‑billion‑dollar market for melanoma and other solid tumors. Replimune’s enterprise value, which has been heavily tied to RP1, is now under pressure, and the company must seek additional funding or shift focus to other pipeline assets.
Replimune reported a net loss of $247.3 million for the fiscal year ended March 31 2025, and held $483.8 million in cash and short‑term investments as of that date. The cash position is expected to support operations into the fourth quarter of 2026, but the CRL will likely accelerate the need for new capital.
The market reacted negatively to the announcement, with analysts noting the loss of a key product candidate and the uncertainty it introduces into the company’s growth trajectory. The rejection also raises concerns about the robustness of Replimune’s clinical development strategy and the broader viability of oncolytic virus therapies.
Replimune’s leadership has indicated that the company will reassess its strategy and may pivot to other candidates such as RP2. The company’s valuation will likely be recalibrated to reflect the reduced probability of regulatory approval for RP1 and the need for additional investment to sustain its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.